

Contents lists available at ScienceDirect

# Ageing Research Reviews



journal homepage: www.elsevier.com/locate/arr

# Benefits and harms of exercise therapy in people with multimorbidity: A systematic review and meta-analysis of randomised controlled trials

Check for updates

Alessio Bricca <sup>a,b,\*</sup>, Lasse K. Harris<sup>a,b</sup>, Madalina Jäger<sup>a,b</sup>, Susan M. Smith<sup>c</sup>, Carsten B. Juhl<sup>a,d</sup>, Søren T. Skou<sup>a,b</sup>

<sup>a</sup> Research Unit for Musculoskeletal Function and Physiotherapy, Department of Sports Science and Clinical Biomechanics, University of Southern Denmark, 5230, Odense M, Denmark

<sup>b</sup> Department of Physiotherapy and Occupational Therapy, Næstved-Slagelse-Ringsted Hospitals, Region Zealand, 4200, Slagelse, Denmark

<sup>c</sup> HRB Centre for Primary Care Research, Department of General Practice, Royal College of Surgeons in Ireland (RCSI), Dublin, Ireland

<sup>d</sup> Department of Physiotherapy and Occupational Therapy, University Hospital of Copenhagen Herlev and Gentofte, Copenhagen, Denmark

#### ARTICLE INFO

Keywords: Multimorbidity Exercise Quality of life Physical function Depression Anxiety ABSTRACT

*Objectives*: To investigate the benefits and harms of exercise therapy on physical and psychosocial health in people with multimorbidity.

*Design:* Systematic review of randomised controlled trials (RCTs). Data sources MEDLINE, EMBASE, CENTRAL and CINAHL from 1990 to April 20th, 2020 and Cochrane reviews on the effect of exercise therapy for each of the aforementioned conditions, reference lists of the included studies, the WHO registry and citation tracking on included studies in Web of Science.

*Eligibility criteria for study selection:* RCTs investigating the benefit of exercise therapy in people with multimorbidity, defined as two or more of the following conditions: osteoarthritis (of the knee or hip), hypertension, type 2 diabetes, depression, heart failure, ischemic heart disease, and chronic obstructive pulmonary disease on at least one of the following outcomes: Health-related quality of life (HRQoL), physical function, depression or anxiety.

*Summary and quality of the evidence:* Meta-analyses using a random-effects model to assess the benefit of exercise therapy and the risk of non-serious and serious adverse events according to the Food and Drug Administration definition. Meta-regression analyses to investigate the impact of pre-specified mediators of effect estimates. Cochrane 'Risk of Bias Tool' 2.0 and the GRADE assessment to evaluate the overall quality of evidence.

*Results*: Twenty-three RCTs with 3363 people, testing an exercise therapy intervention (mean duration 13.0 weeks, SD 4.0) showed that exercise therapy improved HRQoL (standardised mean difference (SMD) 0.37, 95 % CI 0.14 to 0.61) and objectively measured physical function (SMD 0.33, 95 % CI 0.17 to 0.49), and reduced depression symptoms (SMD -0.80, 95 % CI -1.21 to -0.40) and anxiety symptoms (SMD -0.49, 95 % CI -0.99 to 0.01). Exercise therapy was not associated with an increased risk of non-serious adverse events (risk ratio 0.96, 95 % CI 0.53–1.76). By contrast, exercise therapy was associated with a reduced risk of serious adverse events (risk ratio 0.62, 95 % CI 0.49 to 0.78). Meta-regression showed that increasing age was associated with lower effect sizes for HRQoL and greater baseline depression severity was associated with greater reduction of depression symptoms. The overall quality of evidence for all the outcomes was downgraded to low, mainly due to risk of bias, inconsistency and indirectness.

*Conclusions:* Exercise therapy appears to be safe and to have a beneficial effect on physical and psychosocial health in people with multimorbidity. Although the evidence supporting this was of low quality, it highlights the potential of exercise therapy in the management and care of this population.

E-mail address: abricca@health.sdu.dk (A. Bricca).

https://doi.org/10.1016/j.arr.2020.101166

Received 27 May 2020; Received in revised form 6 August 2020; Accepted 26 August 2020 Available online 5 September 2020

1568-1637/© 2020 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

<sup>\*</sup> Corresponding author at: Research Unit for Musculoskeletal Function and Physiotherapy, Institute of Sports Science and Clinical Biomechanics, University of Southern Denmark, Campusvej 55, 5230, Odense M, Denmark.

# 1. Introduction

Multimorbidity, the coexistence of two or more chronic conditions, is as a priority for global health research (Anon., 2018). Compared to people living with only one chronic condition, people with multimorbidity are more likely to die prematurely, to be admitted to and have an increased length of stay at the hospital, (Menotti et al., 2001; Vogeli et al., 2007) in addition to having poorer physical and psychosocial health, higher intake of multiple drugs and increased health care utilization (Bayliss et al., 2004; Fortin et al., 2006, 2004). The increasing burden and complexity of multimorbidity challenge current standards of care, which focus on single-disease management approaches rather than individualised care (Pefoyo et al., 2015; Sinnott et al., 2013). One approach to deal with the complexity of multimorbidity is to focus on specific combination of conditions, linked by physiological factors and risk factors (Smith et al., 2018, 2013).

Osteoarthritis of the knee or hip, hypertension, type 2 diabetes, depression, heart failure, ischemic heart disease, and chronic obstructive pulmonary disease are among the leading causes of global disability, affect hundreds of millions of people around the world, and often coexist (Global Burden of Disease Study 2013 Collaborators, 2015). As an example, two out of three people with osteoarthritis have one or more other chronic conditions (Wesseling et al., 2013), with heart failure, ischemic heart disease, hypertension, type 2 diabetes, depression and chronic obstructive pulmonary disease being some of the most common (Reeuwijk et al., 2010). These conditions share a common risk factor (physical inactivity) and pathogenesis (systemic low-grade inflammation) which may trigger a cascade of reactions resulting in the development of a 'vicious cycle' of chronic diseases and poor outcomes (Gleeson et al., 2011; Pedersen and Saltin, 2015).

Several systematic reviews investigating the effect of exercise therapy have demonstrated the safety and benefits of exercise therapy on each of the aforementioned individual conditions, (Bartels et al., 2016; Cornelissen and Smart, 2013; Fransen et al., 2015; Long et al., 2019; Puhan et al., 2016) and clinical guidelines recommend exercise therapy as the cornerstone of treatment (National Institute for Health and Care Excellence, 2013). On the contrary, the few existing multimorbidity guidelines, summarised in a systematic review (Muth et al., 2019), encourage a healthy lifestyle, including regular physical activity, but do not include specific recommendations for exercise therapy, (Muth et al., 2019) which is among the top 10 research priorities for people with multimorbidity (Parker et al., 2019). Moreover, the interventions for people with multimorbidity evaluated so far have shown minor and negligible effects on important outcomes for people with multimorbidity such as health-related quality of life and function (Salisbury et al., 2018; Smith et al., 2016). One of the key features of exercise therapy is its anti-inflammatory effects at cellular, tissue and organ level as well as its positive psychosocial and physiological effects such as increase in muscle strength, improved blood pressure regulation and insulin sensitivity (Gleeson et al., 2011; Pedersen and Saltin, 2015). The positive effects of exercise therapy may hence disrupt the 'vicious cycle' of systemic inflammation and improve physical and psychosocial health in people with multimorbidity. This highlights the importance of investigating whether exercise therapy can be recommended as a cornerstone treatment also for people with multimorbidity. No previously published systematic reviews exist on this topic.

We therefore performed a systematic review of randomised controlled trials (RCTs) on the benefits and harms of exercise therapy in people with multimorbidity defined as at least two of the following conditions: osteoarthritis of the knee or hip, hypertension, type 2 diabetes, depression, heart failure, ischemic heart disease, and chronic obstructive pulmonary disease on health-related quality of life, physical function, depression and anxiety.

#### 2. Methods

This systematic review was guided by the recommendations for performing systematic reviews in the Cochrane Handbook (Higgins et al., 2019) and the reporting was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (Moher et al., 2009).

# 2.1. Protocol

The protocol for this systematic review has been published, (Bricca et al., 2020) and it was registered at PROSPERO (CRD42020150628). The statistical analysis plan was made publicly available on the Open Science Framework website (Foster and Deardorff, 2017) (https://osf. io/38fcg/) before the title and abstract (TIAB) screening phase was initiated.

# 2.2. Eligibility criteria

# 2.2.1. Study design and participants

RCTs published in peer-reviewed journals. We included studies, with adult (>18 years old), reporting at least 80 % of participants with two or more of the following conditions: osteoarthritis of the knee or hip, heart failure, ischemic heart disease, hypertension (systolic blood pressure >90 and diastolic blood pressure >140), type 2 diabetes mellitus, chronic obstructive pulmonary disease and depression as defined by the studies or calculated based on baseline participants characteristics. This pragmatic approach was pre-specified and adopted in an effort to capture all the studies which included people with multimorbidity, given the expected inconsistency of reporting of the conditions across trials.

# 2.2.2. Intervention

We included exercise therapy interventions with or without additional pharmacotherapy or other adjuvant interventions (e.g. weight loss), based in all settings, including at least 80 % of participants with multimorbidity as defined in our study. Exercise therapy is defined as 'a regimen or plan of physical activities designed and prescribed for specific therapeutic goals with the purpose of restoring normal physical function or to reduce symptoms caused by diseases or injuries' (Caspersen et al., 1985).

We excluded interventions not delivering a structured exercise therapy programme such as providing only a pedometer or booklet to the participants without a specific plan for general physical activity.

#### 2.2.3. Comparator

We included studies comparing exercise therapy interventions to usual/standard care (e.g. counselling from their health care provider), at the time the trial was conducted, and comparator groups non-exposed such as wait-and-see and placebo treatments.

#### 2.2.4. Outcomes

We included studies assessing at least one of the following outcomes:

- Physical health: Objectively measured and self-reported physical function (e.g. 6-minute walking test, 36-item Short-Form Health Survey (SF-36))
- Psychosocial health: Health-related quality of life (e.g. EQ-5D questionnaire), depression symptoms and anxiety symptoms (e.g. Hospital Anxiety and Depression Scale),
- Adverse events according to the FDA definition (Anon., 2020) that is any unfavourable and unintended sign, symptom or disease temporally associated with the use of a medicinal (investigational) product whether or not considered related to the medicinal (investigational) product and grouped in serious adverse events such as death, hospitalization, disability or permanent damage, and non-serious adverse events such as pain, falls and fatigue.

The rationale for including these outcomes is based on a consensus study which identified outcomes for multimorbidity intervention studies (Smith et al., 2018) and the fact that they are generic and widely used across the conditions of interest. Additionally, the choice of these outcomes was supported by the patient partner of MOBILIZE who were made aware of the systematic review and outcome measures included.

# 2.3. Literature search

We obtained information from searching MEDLINE via PubMed, EMBASE via Ovid, CINAHL (including preCINAHL) via EBSCO and the CENTRAL with no restriction on language. We only included RCTs published from 1990 since the reporting as well as the treatment of multimorbidity has changed substantially within the last years, up to October 12th, 2019. The search was repeated for the period from October 2019 to April 20<sup>th</sup>, 2020 in the same databases to identify additional studies published before manuscript submission. We also screened the reference lists of the latest Cochrane reviews investigating the effect of exercise therapy on the following conditions: osteoarthritis, hypertension, type 2 diabetes, depression, heart failure, ischemic heart disease, chronic obstructive pulmonary disease, the reference lists of included RCTs. Furthermore, we screened for completed trials in The World Health Organization's International Clinical Trials Registry Platform (ICTRP) http://apps.who.int/trialsearch/ which comprises the 16 primary registries of the WHO registry network and ClinicalTrials. gov, and searched Web of Science (WoS) for studies citing the RCTs included in this systematic review (citations tracking).

#### 2.4. Search method and study selection

The search strategy was developed for MEDLINE (https://osf. io/84vzn/) and was customised for EMBASE, CINAHL and CENTRAL. All terms were searched both as keywords (Mesh) and as text words in title and abstract, if possible. To identify RCTs, we used the Cochrane sensitive search strategy for identifying RCTs. The results of the literature search were uploaded to EndNote X9.3.1. Two reviewers (AB and LKH) independently screened titles and abstracts and all studies deemed eligible by at least one of the reviewers were checked independently in full text by the same two reviewers. Disagreement between the reviewers about inclusion of individual studies was discussed until consensus was reached. When disagreement persisted, a third reviewer (CBJ) was contacted to resolve the disagreement. We checked whether multiple reports from the same study were published by juxtaposing author names, treatment comparisons, sample sizes and outcomes. When multiple reports of the same study provided different study characteristics (e.g. number of participants and presence of one or more chronic conditions) we used the primary publication. We recorded the reasons for excluding full text RCTs.

# 2.5. Data collection

We used a modified version of the Cochrane Collaboration data collection form for intervention reviews: RCTs only (Higgins et al., 2019). When a study had two intervention groups with two different exercise therapy interventions (A and B) and one usual care comparator group (C), we split the comparator group in two groups of smaller sample size and compared A and B versus C, and reported the results as two separate study comparisons. This procedure is in accordance with the Cochrane handbook (Higgins et al., 2019).

We extracted the following data, from the follow-up immediately after the end of the intervention and the follow-ups closest to 12 months, for continuous outcomes (number of participants, mean and standard deviation, standard error or 95 % Confidence Interval) and for categorical outcomes, we extracted adverse events (cases and total number of participants):

- Trial characteristics: location of the trial (e.g. Country), number of patients allocated to the exercise and comparator groups, respectively, number of patients in the intention to treat (ITT) and per protocol analysis, in the intervention and comparator groups, respectively.
- Participant characteristics: Age, % female, body mass index (BMI), socioeconomic status (SES) (studies were labelled as low socioeconomic status when the majority of the participants were described as having low education levels, low income, being unemployed or sample otherwise labelled as 'low SES'), baseline severity and diagnosis of the conditions, and number, type and frequency of other conditions.
- Intervention and comparator characteristics: Components of intervention (e.g. exercise therapy + education), type of intervention/ comparator interventions (aerobic, neuromuscular, strengthening or a combination of those), frequency of the sessions (times per week), intensity of the session (% of maximum pulse, or % of 1 Repetition Maximum), primary mode of delivery (individual, group, self-help), setting (home-based, hospital-based, or clinic/facility/rehabilitation centres based), duration of the interventions (in weeks), supervision (yes, no or a combination), tailoring (intervention developed according to guidelines and individual patients' needs), adherence to intervention (number of sessions attended out of the total number of planned sessions).
- Outcome characteristics: time points assessed and the magnitude of objectively and subjectively measured changes (e.g. change in health-related quality of life, number of adverse events in the intervention and comparator groups). To avoid multiplicity, we used a hierarchy of selection rules for the outcomes. We prioritised data extraction of outcome measures important for the participants (Smith et al., 2018) and generic over disease-specific measures (Bricca et al., 2020). For objectively measured physical function, we prioritised: 1) the 6-minute walking test, 2) Incremental Shuttle Walking Test, 3) any other outcome measure related to daily function (e.g. Chair stand test). For self-reported physical function, we prioritised outcomes in the following order: 1) the 36-item Short-Form Health Survey (SF-36) Physical Function subscale, 2) the SF-36 Role Function subscale, 3) any other self-reported measure of physical function. For health-related quality of life outcomes, we prioritised: 1) the EQ-5D questionnaire, 2) any other health-related quality of life questionnaires, 3) disease-specific health related quality of life questionnaires (e.g. The Minnesota living with heart failure questionnaire). For depression symptoms, we prioritised: 1) The Beck Depression Inventory (BDI), 2) any other depression questionnaire (e.g. the Hospital Anxiety and Depression Scale (HADS depression). For anxiety symptoms, we prioritised: 1) State Trait Anxiety Inventory questionnaire, 2) any other anxiety questionnaire (e.g. HADS anxiety).

If the data could not be extracted from the published studies, we emailed the corresponding author of the study with a checklist including the data we aimed to obtain. If the email we sent bounced back, we contacted the second author and so forth. After three days, we sent a reminder including the last author of the paper. After seven days of the first email, we re-sent the email to the corresponding and last author. A second reminder followed ten days after the first email. We considered the data as missing after not receiving any communication from the authors fifteen days after we sent the first email.

# 2.6. Risk of bias assessment and overall evaluation of the quality of the evidence

Two reviewers (AB and LKH) independently assessed the risk of bias of the included studies using the Cochrane 'Risk of Bias Tool 2.0' (Higgins et al., 2019). Bias was assessed in five distinct domains: Bias arising from the randomisation process or lack of allocation concealment, Bias due to deviations from intended interventions, Bias due to missing outcome data, Bias in measurement of the outcome or delivery of the intervention (blinding), Bias in selection of the reported result. Within each domain, the two reviewers answered one or more signalling questions (e.g. Was the allocation sequence random? Were participants aware of their assigned intervention during the trial?) which lead to judgments of "low risk of bias," "some concerns," or "high risk of bias". The judgments within each domain lead to an overall risk-of-bias judgment for the outcome being assessed (Higgins et al., 2019). The overall quality (or certainty) of evidence for the estimates were evaluated using the GRADE (Grading of Recommendations Assessment, Development and Evaluation) approach (Schünemann et al., 2013). GRADE is a systematic approach to rate the certainty of evidence across studies for specific outcomes. It is based on five domains that involve the methodological flaws of the studies (i.e., risk of bias), the heterogeneity of results across studies (i.e., inconsistency), the generalisability of the findings to the target population (i.e., indirectness), the precision of the estimates and the risk of publication bias.

# 2.7. Synthesis of results

# 2.7.1. Main analyses

We performed meta-analyses using a random-effects model as heterogeneity was expected in participant, intervention and outcome characteristics. For physical function, we performed two separate metaanalyses for objectively and self-reported outcomes, respectively. Standardised mean differences (SMD) with 95 % CIs were calculated for outcome measures of continuous data and adjusted to Hedges g. The magnitude of the effect size of the pooled SMD was interpreted as 0.2 representing a small effect, 0.5 a moderate effect, and 0.8 a large effect (Cohen, 1988). Effect estimates above 0.5 were considered clinically relevant (Cohen, 1988). The relative risk (RR) of serious and non-serious adverse events was estimated separately as the rate of adverse events in the intervention group divided by the rate of adverse events in the control group. A random effects meta-analysis was applied to estimate the overall RR of adverse events in the exercise therapy groups compared with comparator groups (Higgins et al., 2019). Heterogeneity was examined as between-study variance and calculated as the I-squared statistic measuring the proportion of variation in the combined estimates due to between study variance. An I-squared value of 0% indicates no inconsistency between the results of individual trials, and an I-squared value of 100 % indicates maximal inconsistency. Meta-analyses were performed in STATA (16.1) using the 'meta' command.

# 2.7.2. Analysis of subgroups and meta-regression analyses

For the pre-planned sub-group analyses of studies reporting objectively measured physical function with the 6-minute walk test (6MWT), we estimated the weighted mean difference (WMD) between the intervention and comparator groups. Meta-regression analyses were also performed to identify factors (covariates) which predicted better health outcome when more than ten studies provided data for the covariates of interest, in accordance with the Cochrane Handbook recommendations (Higgins et al., 2019). Relevant study-level covariates were defined as those able to decrease the between-study variance Tau-square (and thus inconsistency measured as the I-squared statistic) (Higgins et al., 2019). Pre-identified factors were extracted based on a systematic screening of the latest Cochrane systematic reviews investigating the effect of exercise therapy on each of the individual conditions of interest and input from members of the study team. These factors were pre-specified and made publicly available prior to the title and abstract screening (htt ps://osf.io/zx9vw/), and are related to participant, intervention and outcome measure characteristics and listed in the 'data collection' above. Additionally, we investigated the impact of risk of bias on the estimates for the outcomes of interest by classifying studies at "low risk of bias", "some concerns", or "high risk of bias" according to the

Cochrane Risk of Bias tool 2.0.

#### 2.7.3. Patients' involvement

The MOBILIZE project is committed to patient involvement and has so far included patients living with multimorbidity in all aspects of the decision-making process in the project. Their experiences, needs and preferences play an important role in the development of a novel intervention (Collaborate level on the IAP2 Spectrum of Public Participation).

# 3. Results

# 3.1. Study selection and characteristics

The literature search identified a total of 17,547 unique publications, of which 336 individual RCTs were identified and full texts screened for potential eligibility. We ultimately included 23 RCTs from 24 papers involving 41 study comparisons (Fig. 1). One study was reported in two different papers (Edelmann et al., 2011; Nolte et al., 2015). We included them all since they report different outcome measures in different papers and counted them as one study. The number of study comparisons exceed the number of studies because when several intervention groups were included in a study, the between-group difference was reported for each possible comparison, at different follow-ups.

The included studies were conducted across 17 countries, including Europe, (Edelmann et al., 2011; Nolte et al., 2015; Pibernik-Okanovic et al., 2015; Oerkild et al., 2012; Hinrichs et al., 2016; Koukouvou et al., 2004; Bernocchi et al., 2018a; Campo et al., 2020; Asa et al., 2012; Kulcu et al., 2007; Rodriguez-Manas et al., 2019) USA (Blumenthal et al., 2012a; de Groot et al., 2019; Gary et al., 2012, 2010; Gary et al., 2004; Gretebeck et al., 2019; Schneider et al., 2016; Blumenthal et al., 2012b), Australia (Leung et al., 2013), and Asia (Leung et al., 2019; Keihani et al., 2014; Abdelbasset et al., 2019; Soliman and Abdelbasset, 2019). The characteristics of the included studies are reported in Table 1.

#### 3.2. Participants

The most common conditions reported in the 23 RCTs (3363 people) The most common conditions reported in the 23 RCTs (3363 people) were heart failure in 16 studies, depression and type 2 diabetes in 15 studies each, hypertension in 14 studies, chronic obstructive pulmonary disease in 6 studies and osteoarthritis of the knee or hip in 4 studies each. The number of conditions reported per study varied from two to seven and the most common combinations of conditions were heart failure and depression, (Koukouvou et al., 2004; Kulcu et al., 2007; Blumenthal et al., 2012a; Gary et al., 2010; Blumenthal et al., 2012b; Keihani et al., 2014; Abdelbasset et al., 2019; Bernocchi et al., 2018b) type 2 diabetes and depression (Pibernik-Okanovic et al., 2015; de Groot et al., 2019; Schneider et al., 2016), and hypertension and type 2 diabetes (Rodriguez-Manas et al., 2019; Gretebeck et al., 2019; Leung et al., 2019) (Table 1).

# 3.3. Intervention and comparator groups

Aerobic exercise was the most commonly applied type of exercise therapy (n = 11), (Oerkild et al., 2012; Asa et al., 2012; Kulcu et al., 2007; Blumenthal et al., 2012a; de Groot et al., 2019; Gary et al., 2010, 2004; Blumenthal et al., 2012b; Keihani et al., 2014; Abdelbasset et al., 2019; Soliman and Abdelbasset, 2019) followed by exercise programmes combining aerobic, strengthening, balance and flexibility exercises (n = 8), (Edelmann et al., 2011; Nolte et al., 2015; Pibernik-Okanovic et al., 2015; Hinrichs et al., 2016; Koukouvou et al., 2004; Campo et al., 2020; Gary et al., 2012; Schneider et al., 2016; Bernocchi et al., 2018b), and Tai Chi (n = 2) (Leung et al., 2013, 2019), or resistance training alone (n = 2), (Rodriguez-Manas et al., 2019; Gretebeck et al., 2019). All the included trials provided total or partial




Fig. 1. Flow chart of the study selection process. RCT = Randomised controlled trial.

supervision of the exercise sessions. Adherence to the exercise therapy sessions varied widely from 51 % to 94 % of the planned exercise sessions. Interventions were delivered individually (Edelmann et al., 2011; Nolte et al., 2015; Kulcu et al., 2007; Rodriguez-Manas et al., 2019; Keihani et al., 2014), in group (Pibernik-Okanovic et al., 2015; Koukouvou et al., 2004; Asa et al., 2012; Blumenthal et al., 2012a; de Groot et al., 2019; Gretebeck et al., 2019; Schneider et al., 2016; Blumenthal et al., 2012b; Leung et al., 2013, 2019), or as self-help (Oerkild et al., 2012; Hinrichs et al., 2016; Campo et al., 2020; Gary et al., 2012, 2010, 2004; Abdelbasset et al., 2019; Soliman and Abdelbasset, 2019; Bernocchi et al., 2018b), (i.e. participants were recommended to exercise by themselves with a structured programme) with or without partial supervision. Exercise interventions were performed at home (45 %), at a fitness centre or clinical medical centre (45 %) or at a hospital (10 %). Comparator groups varied widely and included usual care, medication, cognitive behavioural therapy, education about health conditions, consultations with General Practitioners and stretching and flexibility exercises (Table 1).

# 3.4. Outcomes

Health-related quality of life was reported in thirteen RCTs (Oerkild et al., 2012; Hinrichs et al., 2016; Koukouvou et al., 2004; Campo et al.,

2020; Asa et al., 2012; Kulcu et al., 2007; de Groot et al., 2019; Gary et al., 2012, 2010; Gary et al., 2004; Leung et al., 2013, 2019; Bernocchi et al., 2018b). Physical function was reported in fifteen RCTs of which thirteen assessed physical function objectively (Edelmann et al., 2011; Oerkild et al., 2012; Hinrichs et al., 2016; Campo et al., 2020; Asa et al., 2012; Rodriguez-Manas et al., 2019; de Groot et al., 2019; Gary et al., 2012, 2010; Gary et al., 2004; Gretebeck et al., 2019; Leung et al., 2013; Bernocchi et al., 2018b), and two subjectively (Leung et al., 2019; Keihani et al., 2014). Depression symptoms and anxiety symptoms were reported in fifteen, (Oerkild et al., 2012; Koukouvou et al., 2004; Asa et al., 2012; Kulcu et al., 2007; Blumenthal et al., 2012a; Gary et al., 2012, 2012, 2010; Gary et al., 2004; Schneider et al., 2016; Leung et al., 2013; Keihani et al., 2014; Abdelbasset et al., 2019; Soliman and Abdelbasset, 2019) and six studies (Oerkild et al., 2012; Koukouvou et al., 2004; Asa et al., 2012; Kulcu et al., 2007; Leung et al., 2013; Keihani et al., 2014), respectively. Characteristics of the outcome measures are reported in Table 1.

# 3.5. Effect of exercise therapy on health-related quality of life

Thirteen of the 23 studies (including 15 study comparisons) were included in the meta-analysis. Exercise therapy, average duration 13.3 weeks (SD 4.8), promoted a small improvement in HRQoL (SMD 0.37,

Authors, year and study acronym	Country, study design and setting	Condition type and prevalence	Age (mean), gender and BMI (mean)	Intervention characteristics	Duration (minutes), frequency, intensity, length and adherence to the exercise intervention	Comparator characteristics	Outcomes and (outcome measure)	Pre-specified primary outcome
		D (100 %)	52 years		60 min (10 min		Anxiety (HADS-A)	
Koukouvou et al. 2004 (39)	Greece, 2-arm RCT, Outpatient fitness centres	HF (100 %)	0% female	Supervised group- based, aerobic and strengthening exercise	warm-up and 10 min cool down), 4 times per week for 26 weeks at a	Usual care	(HADS-A) Depression (BDI)	No protocol found
		H (12 %)	BMI 28	excitise	moderate intensity. Adherence 78 %.		HRQoL (QLI)	
	USA, 2-arm RCT,	HF (100 %)	68 years				Depression (GDS)	
		H (88 %)		Partially	40 min (5 min warm-up and 5 min		HRQoL (MLHFQ)	
Gary et al. 2004(49)	Home-based	KOA (68 %), D (44 %) COPD (34 %) T2DM (31 %)	100 % female BMI 34	supervised self- help aerobic exercise and health education	cool down), 3 times per week for 12 weeks at a moderate intensity. Adherence 85 %	Health education	PF(6MWT)	No protocol found
		%) D (100 %)	59 years		60 min (5 min		Anxiety	
Kulcu et al. 2007(43)	Turkey, 2-arm RCT, Cardiopulmonary rehabilitation clinic	HF (100 %)	27 % female	Supervised, individual, aerobic exercise	warm-up and 5 min cool down), 3 times per week for 8 weeks at a moderate intensity	Usual care	(TRAIT) Depression (BDI) HRQoL (HQOL)	No protocol found
		D (100 %)	66 years	Partially supervised, self- help:	45 min, 3 times per week for 12 weeks at a moderate	3) Usual care	Depression (HADS-D)	
Gary et al. 2010(48)	USA, 4-arm RCT, Home-based	HF (100 %) H (88 %)	57 % female	<ol> <li>Aerobic exercise</li> <li>CBT and</li> </ol>	intensity. Adherence 82 %.	4) CBT	HRQoL (MLHFQ)	No protocol found
		T2DM (32 %)		aerobic exercise, and health education			PF (6MWT)	
Åsa et al.	Sweden, 2-arm RCT,	D (100 %),	61 years	Supervised,	45 min, 3 times a week for 8 weeks at		HRQoL (MLHFQ)	
2012(42)	Outpatient Centre- based	T2DM (100 %)	20 % female BMI 29	group-based, aquatic exercise	a low to moderate intensity. Adherence 92 %	Usual care	PF (6MWT)	No protocol found
Blumenthal		D (100 %)	64 years 32 %		30 min (warm up and cool down NR)	1) Sertraline		
et al. 2012 (UPBEAT) (45)	USA, 3-arm RCT	HF (100 %) H (19 %)	female BMI 31	Supervised, group-based aerobic exercise	3 times per week for 16 weeks at a moderate intensity.	2) Placebo pill (up to 200 mg (4 pills)	Depression (HADS-D)	Depression
		D (100 %)	Dini oʻi		Adherence 94 % 60 min (10 min			
Blumenthal et al. 2012 (HF-	USA, Canada and France, 2-arm RCT, Clinical medical	HF (100 %) H (61 %)	56 years, 28 % female,	Supervised, group-based	warm-up and 10 min cool down) 3 times per week for	Usual care	Depression (BDI-II)	Composite of all- cause mortality and all-cause
ACTION) (52)	centres	DM* (10 %)	BMI 31	aerobic exercise Partially	12 weeks at a moderate intensity. Adherence 41 % Aerobic exercise: 60 min (10 min			hospitalisation rates
		HF (100 %)	60 years	supervised, self- help aerobic and strengthening exercise and health education	warm-up and 10 min cool down) 3 times per week for 12 weeks at a moderate intensity	Placebo exercise	Depression (BDI)	
Gary et al. 2012(47)	USA, 2-arm RCT, Home-based	D (70 %) T2DM (50 %)	50 % female		Resistance exercise: 75 min (10 min warm-up and 5 min cool down) 3 times per	(flexibility and stretching)	HRQoL (KCCQ)	No protocol found
		H (50 %)	BMI 34		week for 12 weeks performed at home. Adherence		PF (6MWT)	
		HF (100 %)	77 years		91 %	Usual care		No protocol found

A. Bricca e	et d	ıl.
-------------	------	-----

# Table 1 (continued)

Authors, year and study acronym	Country, study design and setting	Condition type and prevalence	Age (mean), gender and BMI (mean)	Intervention characteristics	Duration (minutes), frequency, intensity, length and adherence to the exercise intervention	Comparator characteristics	Outcomes and (outcome measure)	Pre-specified primar outcome
Derkild et al. 2012(37)	Denmark, 2-arm RCT, Home-based	Н (73 %)	43 % female COPD (28 %), HRQoL (SF- 12pcs)	Self-help aerobic exercise and dietary counselling and, if required, smoking cessation if required	50 min (10 min warm-up and 5 min cool down) 6 times per week for 12 weeks at a low intensity		Anxiety (HADS-A) Depression (HADS-D) BMI 27	
PF (6MWT)	T2DM (22 %)		D (18 %)					
Leung et al. 2013(53)	AUS, 2-arm RCT, Out- patient pulmonary rehabilitation clinic	COPD (100 %) KOA (60 %) H (55 %)	73 years 36 % female BMI 27	Partially supervised, group- based Tai Chi (Sun-style)	60 min (warm up and cool down NR) 2 times per week for 12 weeks at a low intensity	Usual care	Anxiety (HADS-A) Depression (HADS-D) HRQoL (CRQ)	Endurance walking capacity
		IHD (33 %) T2DM (19		exercise and DVD for home exercises	performed at a hospital.		PF (ISWT)	
		%)			Adherence 91 %		Depression	Composite outcome
Volte et al. 2014(35)		HF (100 %) H (82 %)	65 years 56 %	Supervised,	40 min (cycling, 2 times a week) for 4		(PHQ-9) HRQoL (SF-	score including are all-cause mortality,
and Edelmann	Germany, 2-arm RCT,	D (64 %)	female	individual, aerobic and	weeks at a moderate intensity.	Usual care	36 pcs)	hospitalizations, NYHA functional
et al. 2011 (34) (Ex- DHF-P)	Facility-based	T2DM (14 %)	BMI 31	strengthening exercise	From week 5 strengthening exercises 2 times per week	Usual care	PF (6MWT)	class, global self- rated health, maximal exercise capacity, and diastolic function
	Iran, 2-arm RCT,	D (100 %)	61 years		60 min (10–15 minutes warm-up, 30–40 minutes aerobic exercises		Anxiety (BDI- A) Depression (BDI-D)	
Keihani et al 2015(55)	institute of cardiovascular rehabilitation in Isfahan	HF (100 %)	40 % female BMI 29	Supervised, individual, aerobic exercise	and 10–15 minutes of cooling and relaxing) 3 times per week for 8 weeks at a	Usual care	PF (SF-36 PF)	No protocol found
		D (100 %)	66 years	Supervised,	moderate intensity 75 min (warm-up,	1) Enhanced usual		
Pibernik- Okanović et al. 2015	Croatia, 2-arm RCT, Tertiary diabetes	T2DM (100	54 % female	group-based aerobic and strengthening	flexibility, strengthening and stretching	care 2)	Depression (CES-D)	Depression
(36)	clinic	%)	BMI 30	exercise and health education	exercises) for once a week for 6 weeks	Psychoeducation	()	
		D (100 %)	53 years 100 %	Supervised, group-based,				
Schneider	USA, 2-arm RCT, University of	T0D14 (100	female	physical activities (walking, Zumba, Pilates, step	90 min (warm up 15 min and cool down 10 min) 2	Enhanced Usual Care (phone calls	Depression	Depression and
et al. 2016 (51)	Massachusetts Medical School's	T2DM (100 %)	BMI 31	aerobics, cardio- kickboxing, and power yoga) and behavioural activation	times per week for 12 weeks at a moderate intensity. Adherence 51 %	to inform participants on their condition)	symptoms (BDI-II)	HbA1c
Hinrichs et al. 2016 (Homefit) (38)	Germany, 2-arm RCT, Home-based	H (90 %) KOA (60 %) HOA (46 %) T2DM (40 %) HF (33 %) IHD (29 %) COPD (22	80 years 74 % female BMI 31	Partially supervised, self- help strength, flexibility, balance and aerobic (walk outside) exercise and physical activity counselling	Aerobic: 30 min 5 days per week for 12 weeks at a moderate intensity Mixed exercises: 3 $\times$ 10 or 15 repetitions for strength, flexibility, balance exercises 2 or more per week for 12	Health education	PF (Chair rise), HRQoL (Medical Outcomes Study 8-item Short-Form Survey)	PF

(continued on next page)

# Table 1 (continued)

Authors, year and study acronym	Country, study design and setting	Condition type and prevalence	Age (mean), gender and BMI	Intervention characteristics	Duration (minutes), frequency, intensity, length	Comparator characteristics	Outcomes and (outcome measure)	Pre-specified primary outcome
			(mean)		and adherence to the exercise intervention			
		COPD (100 %)	71 years 18 %	Partially	Up to 30–45 min of aerobic exercises and up to 30–40			
Bernocchi et al. 2018 (58)	Italy, 2-arm RCT, Home-based	D (100 %)	female BMI 28	supervised, self- help, aerobic and callisthenic exercises and	min of muscle reinforcement exercises, up to 7 days a week for 16	Usual Care	HRQoL (MLHFQ), PF (6MWT)	PF
		D (100 %)	F2	health education	weeks at a moderate intensity. Adherence 93 %			
Abdelbasset et al. 2019 (56)	Saudi Arabia, 2-arm RCT, Home-based	D (100 %), HF (100 %) H (20 %)	53 years old, 28 % female, BMI 30	Partially supervised, self- help aerobic exercise	60 min, 3 times per week for 12 weeks at a moderate intensity	Usual care	Depression (PHQ-9)	No protocol found
			56 years	Partially supervised, group- based:	50 min (10 min	1) CBT	Depression (BDI-II)	
de Groot et al. 2019 (ACTIVE II)	USA, 2-arm RCT, Community fitness centers	D (100 %), T2DM (100 %)	77 %	1) Aerobic exercise 2) Aerobic	warm up and 10 min cool down) 2 times per week for		HRQoL (SF- 12 pcs)	Depression
(46)	centers	70)	female	exercise and CBT. All participants received a health education booklet	12 weeks at a moderate intensity	2) Usual care	PF (6MWT)	
Leung et al.	Hong Kong, 2-arm RCT, Outpatient	H (100 %)	64 years old, 48 %	Supervised,	60 min (10 min warm up and 10 min cool down) 2	Usual care	HRQoL (SF- 12pcs)	
2019(54)	clinic of a community-based hospital	T2DM (96 %)	female, BMI 27	group-based, Tai Chi (Yang-style)	times per week for 12 weeks at a low intensity. Adherence 81 %		PF (SF-12 PF)	No protocol found
Rodriguez-	Europe (Belgium, Czech Republic, United Kingdom,	T2DM (100 %)	78 years 49 %	Supervised, individual,	45 min 2 times per			
Manas et al. 2019 (MID-	France, Germany, Italy, and Spain),	H (100 %)	female	strengthening exercise and health and	week for 18 weeks at a moderate intensity.	Usual care	PF (SPPB)	PF
Frail)(44)	cluster 2-arm RCT, hospital or primary care site	HF (9%)	BMI 30	nutritional education	Adherence 82 %			
Soliman and Abdelbasset 2019(57)	Saudi Arabia, 2-arm RCT, Home-based	COPD (100 %), D (100 %)	66 years 20 % female BMI 29	Self-help aerobic exercise	3 times per week for 12 weeks a moderate intensity	Usual care	Depression (PHQ-9)	No protocol found
		T2DM (100 %)	71 years	Supervised group- based:	50 . (10 .			
Gretebeck et al. 2019 (50)	USA, 3-arm RCT, Outpatient centre- based	H (83 %)	61 % female	1) Circuit training and home programme to optimize physical activity	50 min (10 min warm up and 10 min cool-down) 3 times per week for 10 weeks at a	Placebo exercise (flexibility and Toning exercises) and health education	PF (6MWT)	PF and physical activity
		A* (36 %)	BMI 33	<ol> <li>Circuit training and health education</li> </ol>	moderate intensity			
Campo et al.	Italy, 2-arm RCT,	HF (100 %) H (86 %)	77 years 23 %	Partially supervised, self-	20 min aerobic exercise plus		HRQoL (EuroQol-	
2020(41)	Home-based	T2DM (30 %)	female BMI 27	help aerobic and calisthenic exercise	calisthenic exercises, 3 times per week	Health education	VAS), PF (10 m gait speed)	PF

 $A^*$  = Arthritis, not specified which form (e.g. osteoarthritis), BDI = Beck depression inventory, BDI-II = Beck depression inventory II, BMI = Body mass index, CES-D = Center for Epidemiologic Studies Depression Scale, COPD = chronic obstructive pulmonary disease, D = Depression, EuroQol-VAS = EQ quality of life visual analogue scale, GDS = Geriatric depression scale, H=Hypertension, HF = heart failure, HADS-D/A=Hospital and anxiety depression scale for depression(D) or anxiety (A), HbA1c= Haemoglobin A1c, HOA=Hip osteoarthritis, HQOL= Hacettepe Quality of Life Questionnaire, HRQoL = health related quality of life, ISWT = Incremental Shuttle Walk Test, MLHFQ = Minnesota Living with Heart Failure Questionnaire, KCCQ = Kansas City Cardiomyopathy Questionnaire, KOA = knee osteoarthritis, PF = physical function, 6MWT = six-minute walking test, RCT = randomised controlled trial, PHQ-9=Patient Health Questionnaire-9, QLI = Quality of Life Index, SF-12 = 12-Item Short Form Health Survey, SF-36 = 36-Item Long Form Health Survey, SPPB = Short Physical Performance Battery), T2DM = type 2 diabetes mellitus, TRAIT = Trait anxiety Inventory.

95 % CI 0.14 to 0.61;  $I^2 = 63.35$  %) (Fig. 2). Meta-regressions indicated that increasing age was associated with lower effect sizes (slope -0.03, 95 % CI -0.05 to -0.01), suggesting that for each additional year in the study, the effect size was reduced by 0.03 SDs (Supplementary Table 1).

When including follow-up closest to 12-month post randomisation, mean 39.7-week (SD 14.2), exercise therapy promoted a small effect on HRQoL (mean n = 5, SMD 0.35, 95 %CI 0.18 to 0.52;  $I^2 = 22.41$  %) (Supplementary Fig. 1).

# 3.6. Effect of exercise therapy on objectively measured physical function

Thirteen of the 23 studies (including 16 study comparisons) were included in the meta-analysis. Exercise therapy, average duration 12.8 weeks (SD 3.7), promoted a small improvement on objectively measured physical function (SMD 0.33, 95 % CI 0.17 to 0.49,  $I^2 = 50.02$  %) (Fig. 3). In studies assessing objectively measured physical function using the 6MWT (n = 10) exercise therapy promoted an improvement of 42.96 m (95 % CI 21.10–64.81;  $I^2 = 37.24$  %) (Fig. 4).

When including follow-up closest to 12-month post randomisation, mean 33.5-week (SD 15.4), exercise therapy promoted a small improvement in objectively measured physical function (n = 6, SMD 0.38, 95 %CI 0.15 to 0.61;  $I^2 = 60.08$  %) (Supplementary Fig. 2).

#### 3.7. Effect of exercise therapy on self-reported physical function

Two of the 23 studies were included in this meta-analysis. Exercise therapy, average duration 10.0 weeks (SD 2.0), had no effect on self-reported physical function, assessed with SF-12 and SF-36 physical function subscale (MD 7.07, 95 %CI -9.10–23.23;  $I^2 = 93.03$  %) (Fig. 5).

# 3.8. Effect of exercise therapy on depression symptoms

Fifteen of the 23 studies (including 19 study comparisons) were included in the meta-analysis. Exercise therapy, average duration 13.2 weeks (SD 4.3), promoted a large reduction in depression symptoms

(SMD -0.80, 95 % CI -1.20 to -0.39;  $I^2 = 89.98$  %) (Fig. 6).

Meta-regression showed that studies including participants with higher levels of depression were associated with higher reduction in depression symptoms (SMD -0,04, 95 % CI -0.07 to -0.02) Supplementary Fig. 3), suggesting that for each additional increase in depression score, the effect size increases by 0.04 SDs (Supplementary Table 1).

When including follow-up closest to 12-month post randomisation, mean 39.7-week (SD 14.5), exercise therapy had no effect on depression (n = 6; SMD -0.08, 95 % CI -0.23 to 0.07;  $I^2 = 9.58$  %) (Supplementary Fig. 4).

# 3.9. Effect of exercise therapy on anxiety symptoms

Six of the 24 studies (including six study comparisons) were included in the meta-analysis investigating the effect of exercise therapy on anxiety. Exercise therapy (mean 13.2-week, SD 13.4) appeared to have a moderate effect on anxiety (SMD -0.49, 95 % CI -0.99 to 0.01;  $I^2 = 71.02$ %) (Fig. 7). Only one study assessed long term effects (52-week followup) of exercise on anxiety symptoms reporting no effect (SMD 0.03, 95 % CI -0.58 to -0.64).

#### 3.10. Adverse events after exercise therapy in people with multimorbidity

Fourteen of the 23 RCTs reported non-serious adverse events data, of which thirteen were included in separate meta-analyses for serious and non-serious adverse events. One study (de Groot et al., 2019) was not included in the meta-analysis due to insufficient data and this study reported no difference in adverse events in the intervention vs the comparator group. The non-serious adverse events reported were knee, arm or back pain, falls, arrythmias, syncope, fatigue and sexual problems. The serious adverse events reported were hospitalisation, pneumonia, cardiac decompression and uncontrolled ventricular arrythmia, sepsis, and extreme fatigue. Meta-analysis showed no difference of non-serious adverse events (RR 0.96, 95 %CI 0.53–1.76;  $I^2 = 57.49$  %) (Fig. 8). However, exercise therapy reduced the risk of serious adverse

	Т	reatmer	nt		Control			SMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Gary 2004	15	-24	18	13	-28	22	<b></b>	0.19 [ -0.53, 0.92]	5.49
Koukouvou 2004	16	9	1	10	7	1	<b>_</b>	1.76 [ 0.86, 2.66]	4.22
Kulcu 2007	23	129	12	21	125	18		0.24 [ -0.35, 0.82]	6.76
Gary 2010b	16	-27	17	17	-27	20		-0.03 [ -0.70, 0.63]	5.98
Gary 2010a	20	-29	18	15	-26	24		-0.13 [ -0.79, 0.52]	6.08
Åsa 2012	8	43	15	9	35	16		0.49 [ -0.43, 1.41]	4.13
Gary 2012	12	73	19	12	54	23		0.86 [ 0.05, 1.67]	4.83
Oerkild 2012	21	4	.8	19	3	9		-0.46 [ -1.08, 0.15]	6.44
Leung 2013	22	6	5	20	5	1		0.51 [ -0.10, 1.11]	6.56
Hinrichs 2016	106	39	8	103	38	8		0.04 [ -0.23, 0.31]	10.22
Bernocchi 2017	48	10	14	44	.4	14		0.71 [ 0.29, 1.13]	8.55
Leung 2019	18	48	6	17	48	6		-0.02 [ -0.66, 0.63]	6.14
de Groot 2019b	25	46	11	24	37	9		0.89 [ 0.31, 1.47]	6.81
de Groot 2019a	30	44	11	28	38	10		0.53 [ 0.02, 1.05]	7.45
Campo 2020	117	80	15	118	70	22	-	0.53 [ 0.27, 0.79]	10.34
Overall							•	0.37 [ 0.14, 0.61]	
Heterogeneity: τ <sup>2</sup> =	= 0.12,	l <sup>2</sup> = 63.3	5%,	H <sup>2</sup> = 2	.73				
Test of $\theta_i = \theta_j$ : Q(14)	4) = 36	.40, p =	0.00						
Test of $\theta = 0$ : $z = 3$	.18, p	= 0.00							
							-1 0 1 2	3	
Random-effects RE	ML mo	del			Favor	rs cor	nparator Favors exercise	therapy	

Fig. 2. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on health-related quality of life. SMD = Standardised Mean Difference; 95 % CI = 95 % Confidence Interval. <sup>a,b</sup>=two separate study comparisons.

	Т	reatme	nt		Contro	d.		SMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Gary 2004	15	318	100	13	223	124		0.82 [ 0.07, 1.58]	3.56
Gary 2010b	16	401	103	17	291	135		0.89 [ 0.19, 1.59]	3.98
Gary 2010a	20	308	125	15	287	125		0.16 [ -0.49, 0.82]	4.39
Gary 2012	12	411	110	12	306	131		0.84 [ 0.03, 1.65]	3.18
Åsa 2012	8	450	100	9	340	40		1.41 [ 0.39, 2.43]	2.16
Oerkild 2012	21	34	57	19	10	69		0.36 [ -0.25, 0.98]	4.82
Leung 2013	22	388	135	20	386	169		0.01 [ -0.58, 0.61]	5.04
Edelmann 2014	44	569	88	20	568	80		0.01 [ -0.51, 0.53]	5.97
Hinrichs 2016	106	19	6	103	19	7	-#-	0.00 [ -0.27, 0.27]	11.05
Bernocchi 2017	48	60	144	44	-15	96		0.60 [ 0.19, 1.02]	7.77
Gretebeck 2019a	56	438	84	18	414	94		0.28 [ -0.25, 0.81]	5.89
Rodriguez-Manas 2019	451	9	2	513	9	3		0.12 [ -0.01, 0.25]	14.60
de Groot 2019b	25	394	125	24	356	82		0.36 [ -0.20, 0.91]	5.51
de Groot 2019a	30	419	111	28	406	105		0.12 [ -0.39, 0.62]	6.17
Gretebeck 2019b	19	421	101	18	414	94		0.07 [ -0.56, 0.70]	4.63
Campo 2020	117	.8	.3	118	.6	.3	-	0.60 [ 0.34, 0.86]	11.30
Overall							•	0.33 [ 0.17, 0.49]	
Heterogeneity: $\tau^2 = 0.04$ ,	$l^2 = 50$	).02%, I	$H^2 = 2$	.00					
Test of $\theta_i = \theta_j$ : Q(15) = 31	.62, p	= 0.01							
Test of $\theta$ = 0: z = 3.97, p	= 0.00	1						_	
						-	1 0 1 2	3	
Random-effects REML mo	del				Favors	s comp	parator Favors exercise the	ару	

Fig. 3. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on objectively measured physical function. SMD = Standardised Mean Difference; 95 % CI = 95 % Confidence Interval. a,b=two separate study comparisons.

		Treatme	nt		Contro	l.		Mean Diff.	Weight
Study	Ν	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Gary 2004	15	318	100	13	223	124		94.79 [ 11.80, 177.78]	5.36
Gary 2010b	16	401	103	17	291	135		- 109.70 [ 27.60, 191.80]	5.45
Gary 2010a	20	308	125	15	287	125		20.70 [ -63.18, 104.58]	5.27
Gary 2012	12	411	110	12	306	131		— 105.40 [ 8.30, 202.50]	4.17
Åsa 2012	8	450	100	9	340	40		110.00 [ 39.24, 180.76]	6.79
Oerkild 2012	21	34	57	19	10	69		23.40 [ -15.71, 62.51]	13.42
Edelmann 2014	44	569	88	20	568	80		1.00 [ -44.26, 46.26]	11.71
Bernocchi 2017	48	60	144	44	-15	96		75.00 [ 24.47, 125.53]	10.42
Gretebeck 2019a	56	438	84	18	414	94		24.38 [ -21.60, 70.36]	11.53
de Groot 2019b	25	394	125	24	356	82		38.40 [ -20.97, 97.77]	8.60
de Groot 2019a	30	419	111	28	406	105		12.70 [ -43.06, 68.46]	9.30
Gretebeck 2019b	19	421	101	18	414	94		7.34 [ -55.48, 70.16]	7.99
Overall							•	42.96 [ 21.10, 64.81]	
Heterogeneity: τ <sup>2</sup> =	528.	21, l² = 3	37.24	%, H	<sup>2</sup> = 1.59				
Test of $\theta_i = \theta_i$ : Q(11	) = 1	7.92, p =	= 0.08						
Test of $\theta = 0$ : $z = 3$ .	.85, p	= 0.00							
							-100 0 100 2	200	
Random-effects RE	ML m	odel				Favor	s comparator Favors exercise t	herapy	

Fig. 4. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on the 6MWT. 95 % CI = 95 % Confidence Interval.<sup>a</sup>, <sup>b</sup>=two separate study comparisons.

events, including hospitalisation, death, pneumonia and cardia disorders (RR 0.62, 95 %CI 0.49 to 0.78;  $I^2 = 0.00$  %) between the intervention and comparator groups (Fig. 9).

# $3.11. \ {\rm Risk}$ of bias assessment and overall evaluation of the quality of the evidence

Forty-three percent of the included studies were deemed as 'low' risk of bias, while 57 % as 'some concerns' or 'high' risk of bias (Supplementary Fig. 5). The majority of the RCTs applied a proper randomisation process and reported and assessed the outcomes of interest correctly. Also, there was no clear sign of publication bias in the funnel plots of each meta-analysis (Supplementary 6). However, all the studies were judged as 'some concerns' for the 'measurement of the outcome' item since it is not possible to blind participants to exercise interventions. Sensitivity analyses indicated that studies judged as 'some concerns' or 'high' risk of bias reported more favourable results in favour of the intervention groups than studies judged as 'low' risk of bias for the outcomes depression. We therefore downgraded the quality of evidence for depression due to risk of bias. The overall quality of the




Fig. 5. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on self-reported physical function. 95 % CI = 95 % Confidence Interval. <sup>a,b</sup>=two separate study comparisons.

	т	reatmer	nt		Control			SMD	Weight
Study	Ν	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Koukouvou 2004	16	13	3	10	19	5		-1.39 [ -2.24, -0.53]	4.89
Gary 2004	15	4	4	13	7	5		-0.65 [ -1.39, 0.09]	5.16
Kulcu 2007	23	14	8	21	22	12		-0.88 [ -1.49, -0.27]	5.46
Gary 2010b	16	6	4	17	8	6		-0.32 [ -0.99, 0.35]	5.32
Gary 2010a	20	8	6	15	9	5		-0.17 [ -0.82, 0.49]	5.35
Blumenthal 2012a1	337	17	8	316	18	9		-0.16[-0.31, -0.00]	6.16
Åsa 2012	8	4	2	9	5	4		-0.39 [ -1.31, 0.52]	4.74
Oerkild 2012	21	-1	3	19	-1	3		0.03 [ -0.58, 0.64]	5.46
Blumenthal 2012a	18	-8	7	24	-4	7		-0.40 [ -1.00, 0.21]	5.46
Gary 2012	12	9	6	12	13	9		-0.50 [ -1.29, 0.29]	5.05
Blumenthal 2012b	18	-8	7	40	-6	7		-0.20 [ -0.75, 0.35]	5.58
Leung 2013	22	3	3	20	4	4		-0.28 [ -0.88, 0.32]	5.48
Keihani 2015	33	33	9	32	44	11		-1.06 [ -1.57, -0.55]	5.65
Schneider 2016	14	15	14	14	16	7		-0.12 [ -0.84, 0.60]	5.21
Abdelbasset 2019a	23	4	1	12	8	2		-3.02 [ -4.00, -2.04]	4.57
de Groot 2019b	25	9	9	24	11	9		-0.27 [ -0.83, 0.28]	5.57
Abdelbasset 2019b	23	3	1	12	8	2		-3.38 [ -4.43, -2.34]	4.41
Soliman 2019	17	7	2	17	14	3		-2.41 [ -3.28, -1.54]	4.84
de Groot 2019a	30	12	8	28	18	12		-0.63 [ -1.16, -0.11]	5.64
Overall							•	-0.80 [ -1.20, -0.39]	
Heterogeneity: $\tau^2 = 0$ .	70, l² =	89.98%	, H² =	9.98					
Test of $\theta_i = \theta_j$ : Q(18) =	= 107.8	3, p = 0.	00						
Test of $\theta = 0$ : $z = -3.8$	2, p = 0	.00							
							-4 -2 0	2	
Random-effects REML	model					Fav	ors exercise therapy Favors	comparator	

Fig. 6. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on depression symptoms. SMD = Standardised Mean Difference; 95 % CI = 95 % Confidence Interval. <sup>a,b</sup>=two separate study comparisons.

evidence assessed using GRADE, including reasons for downgrading the quality of the evidence, is summarised in Table 2.

#### 4. Discussion

This systematic review included 23 RCTs using various types of exercise therapy administered in different settings and including more than 3300 people with multimorbidity from 17 countries. Although based on low quality of evidence, we found that exercise therapy is safe and effective to improve physical and psychosocial health. The greatest benefits from exercise therapy were reported for depression, anxiety, health-related quality of life and objectively measured physical function. While exercise therapy characteristics had no impact on physical and psychosocial health, younger people may expect greater improvements in health-related quality of life, and people with higher baseline depression may expect greater reduction in depression following an exercise therapy intervention.

# 4.1. Results in context

The exercise therapy types used included aerobic exercise (47 %), strengthening exercise (9%), a combination of these (35 %), and Tai Chi (9%), and were performed at home (45 %), at a fitness centres or clinical medical centre based (45 %) or at a hospital (10 %). The greatest benefits from exercise therapy were observed for depression, followed by anxiety, health-related quality of life and objectively measured physical function. This is in line with the effect of exercise therapy for each of the chronic conditions investigated (Bartels et al., 2016; Fransen et al., 2015; Puhan et al., 2016; Cooney et al., 2013; Stonerock et al., 2015; McCarthy et al., 2015), and exercise RCTs including people with multimorbidity (de Rooij et al., 2017; Martinez-Velilla et al., 2019). When comparing exercise therapy to primary or community care setting

		Freatme			Contro			SMD	Weight
Study	N	Mean	SD	Ν	Mean	SD		with 95% CI	(%)
Koukouvou 2004	16	9	2	10	14	4		-1.74 [ -2.64, -0.84]	13.54
Kulcu 2007	23	56	12	21	63	8		-0.65 [ -1.25, -0.05]	17.97
Åsa 2012	9	5	4	8	3	3		0.53 [ -0.39, 1.45]	13.25
Oerkild 2012	21	-1	4	19	9	3		-0.09 [ -0.69, 0.52]	17.79
Leung 2013	22	3	3	20	6	6		-0.63 [ -1.24, -0.02]	17.78
Keihani 2015	33	48	8	32	51	8		-0.42 [ -0.91, 0.07]	19.68
Overall							+	-0.49 [ -0.99, 0.01]	
Heterogeneity: τ <sup>2</sup> =	= 0.27	7, I² = 71	.02%	5, H <sup>2</sup>	= 3.45				
Test of $\theta_i = \theta_j$ : Q(5)	) = 14	.36, p =	0.01						
Test of $\theta = 0$ : z = -	1.93,	p = 0.05	5						
							-4 -2 0	2	
Random-effects RE	ML m	odel				Fa	vors exercise therapy Favors	comparator	

Fig. 7. Forest plot for the effect of exercise therapy compared to a non-exercise therapy comparator group on anxiety symptoms. SMD = Standardised Mean Difference; 95 % CI = 95 % Confidence Interval.

	Treat	ment	Co	ntrol		Risk Ratio	Weight
Study	Yes	No	Yes	No		with 95% CI	(%)
Koukouvou 2004	0	17	0	10		1.00 [ 0.02, 52.25]	2.12
Gary 2004	0	16	0	16	<b>_</b>	1.00 [ 0.02, 47.55]	2.22
Kulcu 2007	0	28	0	26		1.00 [ 0.02, 48.66]	2.19
Gary 2010a	0	37	0	34		1.00 [ 0.02, 49.12]	2.18
Åsa 2012	2	11	0	10		4.67 [ 0.22, 98.74]	3.39
Blumenthal 2012a	2	33	22	59		0.21 [ 0.05, 0.85]	11.06
Gary 2012	0	12	0	12		1.00 [ 0.02, 46.70]	2.24
Leung 2013	0	23	0	20		1.00 [ 0.02, 48.40]	2.20
Nolte 2014	11	34	0	20		— 17.00 [ 0.51, 571.08]	2.63
Schneider 2016	32	15	7	14		2.04 [ 1.08, 3.86]	20.93
Hinrichs 2016	64	106	66	103	•	0.96 [ 0.74, 1.26]	25.93
Rodriguez-Manas 2019	21	451	44	513	-	0.56 [ 0.34, 0.93]	22.92
Overall					•	0.96 [ 0.53, 1.76]	
Heterogeneity: $\tau^2 = 0.34$ ,	l² = 57.4	49%, ł	<sup>1</sup> ² = 2	.35			
Test of $\theta_i = \theta_i$ : Q(11) = 17	.82, p =	0.09					
Test of $\theta = 0$ : z = -0.12, p	= 0.90						
					1/32 1/2 8 128	_	
Random-effects REML mo	del	C	Decre	ased r	isk of serious AE Increased risk of	serious AE	

Fig. 8. Forest plot non-serious adverse events.

interventions, which include consultations with nurses, physicians and pharmacists aiming at promoting self-management, we observed that for HRQoL and physical function, the improvements promoted by exercise therapy were greater (Salisbury et al., 2018; Smith et al., 2016). However, the indirect comparisons of these interventions, in different multimorbid populations, need to be interpreted with caution.

Exercise therapy appeared to be safe with no risk difference between the exercise therapy and comparator groups on non-serious adverse events. By contrast, exercise therapy reduced the risk for serious adverse events. Although, we were unable to distinguish whether the adverse events were directly related to the interventions, this is promising as adverse events are common in people with chronic conditions (Marengoni and Onder, 2015; Nunes et al., 2016). A systematic review investigating adverse events across all conditions in exercise therapy trials found no risk for an increase of serious adverse events but a 19 % increase in non-serious adverse events (Niemeijer et al., 2019). Differences in risk of non-serious adverse events may be partially explained by the population included and the reduced length of the exercise interventions (on average 13 weeks vs 20 weeks).

# 4.2. Implication for clinical practice

High quality evidence on the effectiveness of different treatments are limited for people with multimorbidity. While future studies are carried out to improve the confidence in the effect of exercise in this population, given that exercise seems safe and beneficial, it can be recommended in clinical practice. People with multimorbidity engaging in an exercise therapy intervention may experience reduced depression and improved health-related quality of life and physical function. These improvements ranged from being not clinically to clinically relevant, with younger people and people with higher depression scores experiencing greater improvements in HRQoL and depression, respectively. For physical function, the improvement observed corresponded to an average increase of 43 m in the 6MWT in favour of the exercise therapy interventions. This improvement is greater than the 30 m cut off for clinical relevance generally used in people with chronic conditions such as chronic obstructive pulmonary disease, lung cancer, coronary artery disease and adults with fear of falling (Bohannon and Crouch, 2017).

	Treat	tment	Co	ntrol		Risk Ratio	Weight
Study	Yes	No	Yes	No		with 95% CI	(%)
Koukouvou 2004	0	17	0	10		1.00 [ 0.02, 52.25]	0.34
Gary 2004	0	16	0	16		1.00 [ 0.02, 47.55]	0.36
Kulcu 2007	1	22	3	18		0.30 [ 0.03, 2.70]	1.11
Gary 2010a	0	37	0	34		1.00 [ 0.02, 49.12]	0.35
Gary 2012	0	12	0	12		1.00 [ 0.02, 46.70]	0.36
Blumenthal 2012a	0	19	0	25		1.00 [ 0.02, 49.53]	0.35
Åsa 2012	0	10	0	10		1.00 [ 0.02, 46.05]	0.36
Leung 2013	0	23	0	20		1.00 [ 0.02, 48.40]	0.35
Nolte 2014	0	45	0	20		1.00 [ 0.02, 66.44]	0.30
Hinrichs 2016	6	106	15	103		0.42 [ 0.17, 1.05]	6.38
Bernocchi 2017	10	55	15	41		0.57 [ 0.28, 1.18]	10.33
Gretebeck 2019a	0	64	0	64		1.00 [ 0.02, 49.63]	0.35
Rodriguez-Manas 2019	52	451	93	513		0.67 [ 0.49, 0.93]	52.33
Campo 2020	23	118	47	117	-	0.57 [ 0.36, 0.89]	26.74
Overall					•	0.62 [ 0.49, 0.78]	
Heterogeneity: $\tau^2 = 0.00$ ,	$I^2 = 0.0$	)0%, H	<sup>2</sup> = 1	.00			
Test of $\theta_i = \theta_j$ : Q(13) = 2.0	06, p =	1.00					
Test of $\theta$ = 0: z = -4.11, p	= 0.00						
					1/64 1/4	4 64	
Random-effects REML mo	del		Dec	reased	risk of serious AE Inci	reased risk of serious AE	



# Table 2Summary of findings.

5 0					
Outcomes	Risk with Non-exposed comparator groups	Exercise therapy vs. non-exercise therapy Effect size (SMD or MD) with 95 % CI	Relative effect (95 % CI)	№ of participants (studies)	Certainty of the evidence (GRADE)
Health-Related Quality of Life	_	SMD 0.37 SD higher (0.14 higher to 0.61 higher)	-	967 (13 RCTs)	LOW a,b
Objectively physical function	-	SMD 0.33 SD higher (0.17 higher to 0.49 higher)	-	2001 (13 RCTs)	□□○○ LOW <sup>a,b</sup>
Self-reported physical function		MD 7.07 SD higher (9.1 lower to 23.23 higher)	-	218 (2 RCTs)	$\square_{d} \bigcirc \bigcirc$ VERY LOW <sup>a,b,</sup>
Depression symptoms	-	SMD 0.8 SD lower (1.21 lower to 0.4 lower)	-	1348 (15 RCTs)	$\square_{d,e} \bigcirc \bigcirc \text{VERY LOW} ^{\text{b,c,}}$
Anxiety symptoms	-	SMD 0.49 SD lower (0.99 lower to 0.01 higher)	-	234 (6 RCTs)	$\square_{c} \bigcirc \bigcirc$ VERY LOW <sup>a,b,</sup>
Non-serious adverse events	154 per 1000	148 per 1000 (82–271)	<b>RR 0.96</b> (0.53–1.76)	1620 (12 RCTs)	□□○○ LOW <sup>a,h</sup>
Serious adverse events	172 per 1000	107 per 1000 (85–135)	<b>RR 0.62</b> (0.49 to 0.78)	1998 (14 RCTs)	□□○○ LOW <sup>a,b</sup>

CI: Confidence interval; SMD: Standardised mean difference; MD: Mean difference; RR: Risk ratio.

**GRADE Working Group grades of evidence High certainty:** We are very confident that the true effect lies close to that of the estimate of the effect **Moderate certainty:** We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different **Low certainty:** Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect **Very low certainty:** We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect. Explanations.

a. Quality of evidence downgraded of one level for indirectness of the population.

b. Quality of evidence downgraded of one level for imprecision of the estimates.

c. Quality of evidence downgraded of one level for inconsistency of the estimates.

d. Quality of evidence downgraded of one level due to risk of bias.

e. Publication bias strongly suspected.

#### 4.3. Implications for future research

This systematic review highlights a need for future, high quality, RCTs evaluating the effects of well-designed exercise therapy interventions in people with multimorbidity. Based on the result of this systematic review, we suggest that future studies should also include people with different combinations of conditions. For example, osteoarthritis, while being the most common joint disease and often associated with more chronic conditions (Wesseling et al., 2013), has been investigated in only four of the included studies (Hinrichs et al., 2016; Gary et al., 2004; Gretebeck et al., 2019; Leung et al., 2013).

In the design of future exercise interventions, given the fact that multimorbidity is heterogeneous, focusing on individualised treatments tailored to people's goals and preferences might also help increase the effect estimates and exercise therapy adherence, which is required for expecting greater improvements on health outcomes (Smith et al., 2013; Fransen et al., 2015). In fact, the improvements observed for short-term follow-ups (i.e. immediately after the end of the intervention) were not

maintained for depression and anxiety at long-term follow-ups (i.e. the follow-ups closest to 12 months), presumably due to a decrease in exercise adherence. Also, particular attention should be given to the choice and reporting of comparator groups (Freedland et al., 2019). This may help explain the inconsistency of effect estimates. Regarding the selection of the outcome measures, we suggest future studies to select primary outcome measures important to the patients (Smith et al., 2018, 2013), as highlighted by a consensus agreement by a group of international researchers working to improve care for people with multimorbidity.

# 4.4. Strengths and limitations

This systematic review with meta-analysis has been conducted and reported according to recommended international guidelines (Higgins et al., 2019; Moher et al., 2009) and it followed a pre-specified protocol (Bricca et al., 2020). Additionally, we have contacted study authors to retrieve missing information from the included RCTs which allowed us to conduct meta-regression analyses with complete data for intervention characteristics such as mode of delivery and setting of the intervention.

This systematic review has limitations. First, among all the conditions included, the majority of the RCTs included people with depression and heart failure and not all studies included 100 % of people with multimorbidity. Additionally, most people of the included studies reported mild to moderate depression severity, limiting the generalisability of the findings to people with other combinations of conditions or more severe depression. However, the combination of the conditions (studies including participants with heart failure and depression vs. studies including participants with different combination of conditions) and the inclusion criteria (80 % of participants with multimorbidity vs. 100 % with multimorbidity) of this systematic review had no impact on effect estimates. Second, the heterogenous nature of the multimorbidity definition and interventions tested reflected the large inconsistency in the effect estimates of the meta-analyses and that positive results may be attributed to combined effects instead of exercise therapy alone. Third, the quality of evidence for the outcomes of interest was low, suggesting that the true effect of exercise therapy may differ from the one reported in this systematic review. Finally, reporting of adverse events was nonconsistent across studies. This is common in exercise trials and highlights the need for harmonising reporting of adverse events (Niemeijer et al., 2019) so that all adverse events are reported regardless of whether they are considered related to the intervention or not.

#### 5. Conclusions

While the low quality of the evidence limits the confidence in our results, exercise therapy appeared to be a safe and beneficial intervention to improve physical and psychosocial health in people with multi-morbidity, highlighting its potential in the management and care of this population.

# Author contributions

STS procured the funding for this systematic review. AB and CBJ designed the search strategy. AB and LKH independently screened title/ abstracts, full texts, extracted data from the included studies, assessed risk of bias and contacted study authors to retrieve additional information. AB and CBJ performed the GRADE assessment. AB did the data analysis, and CBJ provided statistical expertise and SM provided clinical expertise about multimorbidity. AB wrote the first draft of the manuscript and STS provided feedback. All authors read, provided feedback and approved the study design, methods, protocol and manuscript drafts as well as approved the final manuscript. AB is the guarantor and drafted the manuscript.

#### Data statements

The dataset and statistical script necessary to reproduce the analyses presented in the systematic review will be made available online at the Open Science Framework page of the MOBILIZE project (https://osf. io/qk6yg/).

# Dissemination

The findings of this systematic review will be presented at national and international conferences and made available to end-users via infographics, podcasts, press releases and videos.

# Funding

European Research Council (ERC) under the European Union's Horizon 2020 research and innovation programme(MOBILIZE, grant agreement No 801790), Næstved, Slagelse and Ringsted Hospitals' Research Fund and The Association of Danish Physiotherapists Research Fund.

# Role of funder

The funding source was not involved in any aspect of this systematic review protocol.

# Acknowledgements

We would like to thank Gregers Aagaard and Margit Dybkjær, two people living with multiple chronic conditions, and Tue Dybkjær a partner of a person with multimorbidity, for their feedback on the choice of the outcome measures for this systematic review and feedback on the presentation of the findings of this systematic review, respectively. We would also like to thank the MOBILIZE scientific advisory board consisting of Prof. Sallie Lamb, Prof. Alan Silman, Prof. Bente Klarlund Pedersen, Prof. Ewa M. Roos and Prof. Rod Taylor. Additionally, we would also like to thank the authors of the included studies which provided us the data requested via email: Dr. Timo Hinrichs, Prof. Evangelia Kouidi, Dr. Olga Laosa Zafra, Dr. Regina Leung, Prof. Rebecca Gary and Prof. Yeşim Kurtaiş Aytür and Dr Frank Edelmann.

# Appendix A. Supplementary data

Supplementary material related to this article can be found, in the online version, at doi:https://doi.org/10.1016/j.arr.2020.101166.

#### References

- Abdelbasset, W.K., Alqahtani, B.A., Alrawaili, S.M., Ahmed, A.S., Elnegamy, T.E., Ibrahim, A.A., et al., 2019. Similar effects of low to moderate-intensity exercise program vs moderate-intensity continuous exercise program on depressive disorder
- in heart failure patients A 12-week randomized controlled trial. Medicine 98 (32). Anon, 2018. The Lancet - making more of multimorbidity: an emerging priority. Lancet
- 391 (10131), 1637. Anon, 2020. FDA Serious Adverse Event. Available from https://www.fda.gov/safety/
- reporting-serious-problems-fda/what-serious-adverse-e vent. Asa, C., Maria, S., Katharina, S.S., Bert, A., 2012. Aquatic exercise is effective in
- improving exercise performance in patients with heart failure and type 2 diabetes mellitus. Evid.-Based Compl. Altern.Bartels, E.M., Juhl, C.B., Christensen, R., et al., 2016. Aquatic exercise for the treatment
- of knee and hip osteoarthritis. Cochrane Database Syst. Rev. 3, CD005523. Bavliss, E.A., Bavliss, M.S., Ware Jr., J.E., Steiner, J.F., 2004. Predicting declines in
- bayins, E.A., Bayins, W.S., Wate J., J.E., Steiner, J.F., 2004. Freutrum getomes in physical function in persons with multiple chronic medical conditions: what we can learn from the medical problem list. Health Qual. Life Outcomes 2, 47.
- Bernocchi, P., Vitacca, M., La Rovere, M.T., Volterrani, M., Galli, T., Baratti, D., et al., 2018a. Home-based telerehabilitation in older patients with chronic obstructive pulmonary disease and heart failure: a randomised controlled trial. Age Ageing 47 (1), 82–88.
- Bernocchi, P., Vitacca, M., La Rovere, M.T., Volterrani, M., Galli, T., Baratti, D., et al., 2018b. Home-based telerehabilitation in older patients with chronic obstructive

#### A. Bricca et al.

pulmonary disease and heart failure: a randomised controlled trial. Age Ageing 47 (1), 82–88.

- Blumenthal, J.A., Sherwood, A., Babyak, M.A., Watkins, L.L., Smith, P.J., Hoffman, B.M., et al., 2012a. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J. Am. Coll. Cardiol. 60 (12), 1053–1063.
- Blumenthal, J.A., Babyak, M.A., O'Connor, C., Keteyian, S., Landzberg, J., Howlett, J., et al., 2012b. Effects of exercise training on depressive symptoms in patients with chronic heart failure: the HF-ACTION randomized trial. JAMA 308 (5), 465–474.
- Bohannon, R.W., Crouch, R., 2017. Minimal clinically important difference for change in 6-minute walk test distance of adults with pathology: a systematic review. J. Eval. Clin. Pract. 23 (2), 377–381.
- Bricca, A., Harris, K.L., Saracutu, M., Smith, M.S., Juhl, B.J., Skou, S.T., 2020. The benefits and harms of therapeutic exercise on physical and psychosocial outcomes in people with multimorbidity: protocol for a systematic review. J. Comorbidity 10, 1–7.
- Campo, G., Tonet, E., Chiaranda, G., Sella, G., Maietti, E., Bugani, G., et al., 2020. Exercise intervention improves quality of life in older adults after myocardial infarction: randomised clinical trial. Heart.
- Caspersen, C.J., Powell, K.E., Christenson, G.M., 1985. Physical-activity, exercise, and physical-fitness - definitions and distinctions for health-related research. Public Health Rep. 100 (2), 126–131.
- Cohen, J., 1988. Statistical power analysis for the behavioral-sciences. Percept Motor Skill. 67 (3), 1007.
- Cooney, G.M., Dwan, K., Greig, C.A., Lawlor, D.A., Rimer, J., Waugh, F.R., et al., 2013. Exercise for depression. Cochrane Database Syst. Rev. 9, CD004366.
- Cornelissen, V.A., Smart, N.A., 2013. Exercise training for blood pressure: a systematic review and meta-analysis. J. Am. Heart Assoc. 2 (1), e004473.
- de Groot, M., Shubrook, J.H., Hornsby Jr., W.G., Pillay, Y., Mather, K.J., Fitzpatrick, K., et al., 2019. Program ACTIVE II: outcomes from a randomized, multistate community-based depression treatment for rural and urban adults with type 2 diabetes. Diabetes Care 42 (7), 1185–1193.
- de Rooij, M., van der Leeden, M., Cheung, J., van der Esch, M., Hakkinen, A., Haverkamp, D., et al., 2017. Efficacy of tailored exercise therapy on physical functioning in patients with knee osteoarthritis and comorbidity: a randomized controlled trial. Arthritis Care Res. (Hoboken) 69 (6), 807–816.
- Edelmann, F., Gelbrich, G., Dungen, H.D., Frohling, S., Wachter, R., Stahrenberg, R., et al., 2011. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction results of the Ex-DHF (Exercise training in diastolic heart failure) pilot study. J. Am. Coll. Cardiol. 58 (17), 1780–1791.
- Fortin, M., Lapointe, L., Hudon, C., Vanasse, A., Ntetu, A.L., Maltais, D., 2004. Multimorbidity and quality of life in primary care: a systematic review. Health Qual. Life Outcomes 2, 51.
- Fortin, M., Bravo, G., Hudon, C., Lapointe, L., Dubois, M.F., Almirall, J., 2006. Psychological distress and multimorbidity in primary care. Ann. Fam. Med. 4 (5), 417–422.
- Foster, E.D., Deardorff, A., 2017. Open science framework (OSF). J. Med. Libr. Assoc. 105 (2), 203–206.
- Fransen, M., McConnell, S., Harmer, A.R., Van der Esch, M., Simic, M., Bennell, K.L., 2015. Exercise for osteoarthritis of the knee. Cochrane Database Syst. Rev. 1, CD004376.
- Freedland, K.E., King, A.C., Ambrosius, W.T., Mayo-Wilson, E., Mohr, D.C., Czajkowski, S.M., et al., 2019. The selection of comparators for randomized controlled trials of health-related behavioral interventions: recommendations of an NIH expert panel. J. Clin. Epidemiol. 110, 74–81.
- Gary, R.A., Sueta, C.A., Dougherty, M., Rosenberg, B., Cheek, D., Preisser, J., et al., 2004. Home-based exercise improves functional performance and quality of life in women with diastolic heart failure. Heart Lung 33 (4), 210–218.
- Gary, R.A., Dunbar, S.B., Higgins, M.K., Musselman, D.L., Smith, A.L., 2010. Combined exercise and cognitive behavioral therapy improves outcomes in patients with heart failure. J. Psychosom. Res. 69 (2), 119–131.
- Gary, R.A., Cress, M.E., Higgins, M.K., Smith, A.L., Dunbar, S.B., 2012. A Combined Aerobic and Resistance Exercise Program Improves Physical Functional Performance in Patients With Heart Failure A Pilot Study. J. Cardiovasc. Nurs. 27 (5), 418–430.
- Gleeson, M., Bishop, N.C., Stensel, D.J., Lindley, M.R., Mastana, S.S., Nimmo, M.A., 2011. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease. Nat. Rev. Immunol. 11 (9), 607–615.
- Global Burden of Disease Study 2013 Collaborators, 2015. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 386 (9995), 743–800.
- Gretebeck, K.A., Blaum, C.S., Moore, T., Brown, R., Galecki, A., Strasburg, D., et al., 2019. Functional exercise improves mobility performance in older adults with type 2 diabetes: a randomized controlled trial. J. Phys. Act. Health 16 (6), 461–469.
- Higgins, J.P.T.T.J., Chandler, J., Cumpston, M., Li, T., Page, M.J., Welch, V.A., 2019. Cochrane Handbook for Systematic Reviews of Interventions Version 6.0 (Updated July 2019). Cochrane, 2019. Available from. www.training.cochrane.org/handbook.
- Hinrichs, T., Bücker, B., Klaaßen-Mielke, R., Brach, M., Wilm, S., Platen, P., et al., 2016. Home-based exercise supported by general practitioner practices: ineffective in a sample of chronically ill, mobility-limited older adults (the HOMEfit randomized controlled trial). J. Am. Geriatr. Soc. 64 (11), 2270–2279.
- Keihani, D.K., Mokhtari, M., Mokhtari, M., 2014. Cardiac effects of exercise rehabilitation on quality of life,depression and anxiety in patients with heart failure patients. J. Fundam. Mental Health 17 (1), 13–19.

- Koukouvou, G., Kouidi, E., Iacovides, A., Konstantinidou, E., Kaprinis, G., Deligiannis, A., 2004. Quality of life, psychological and physiological changes following exercise training in patients with chronic heart failure. J. Rehabil. Med. 36 (1), 36–41.
- Kulcu, D.G., Kurtais, Y., Tur, B.S., Gulec, S., Seckin, B., 2007. The effect of cardiac rehabilitation on quality of life, anxiety and depression in patients with congestive heart failure. A randomized controlled trial, short-term results. Medicophys. 43 (4), 489–497.
- Leung, R.W., McKeough, Z.J., Peters, M.J., Alison, J.A., 2013. Short-form Sun-style t'ai chi as an exercise training modality in people with COPD. Eur. Respir. J. 41 (5), 1051–1057.
- Leung, L.-L., Chan, A.-K., Sit, J.-H., Liu, T., Taylor-Piliae, R.E., 2019. Tai Chi in Chinese adults with metabolic syndrome: a pilot randomized controlled trial. Complement. Ther. Med. 46, 54–61.
- Long, L., Mordi, I.R., Bridges, C., Sagar, V.A., Davies, E.J., Coats, A.J., et al., 2019. Exercise-based cardiac rehabilitation for adults with heart failure. Cochrane Database Syst. Rev. 1, CD003331.
- Marengoni, A., Onder, G., 2015. Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ 350, h1059.
- Martinez-Velilla, N., Casas-Herrero, A., Zambom-Ferraresi, F., de Asteasu, M.L.S., Lucia, A., Galbete, A., et al., 2019. Effect of exercise intervention on functional decline in very elderly patients during acute hospitalization a randomized clinical trial. JAMA Intern. Med. 179 (1), 28–36.
- McCarthy, B., Casey, D., Devane, D., Murphy, K., Murphy, E., Lacasse, Y., 2015. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst. Rev. 2, CD003793.
- Menotti, A., Mulder, I., Nissinen, A., Giampaoli, S., Feskens, E.J.M., Kromhout, D., 2001. Prevalence of morbidity and multimorbidity in elderly male populations and their impact on 10-year all-cause mortality: the FINE study (Finland, Italy, Netherlands, Elderly). J. Clin. Epidemiol. 54 (7), 680–686.
- Moher, D., Liberati, A., Tetzlaff, J., Altman, D.G., Group, P., 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339, b2535.
- Muth, C., Blom, J.W., Smith, S.M., Johnell, K., Gonzalez-Gonzalez, A.I., Nguyen, T.S., et al., 2019. Evidence supporting the best clinical management of patients with multimorbidity and polypharmacy: a systematic guideline review and expert consensus. J. Intern. Med. 285 (3), 272–288.
- National Institute for Health and Care Excellence, 2013. Physical Activity: Brief Advice for Adults in Primary Care. Public Health Guideline [PH44]. NICE Guideline 2013.
- Niemeijer, A., Lund, H., Stafne, S.N., Ipsen, T., Goldschmidt, C.L., Jorgensen, C.T., et al., 2019. Adverse events of exercise therapy in randomised controlled trials: a systematic review and meta-analysis. Br. J. Sports Med.
- Nolte, K., Herrmann-Lingen, C., Wachter, R., Gelbrich, G., Dungen, H.D., Duvinage, A., et al., 2015. Effects of exercise training on different quality of life dimensions in heart failure with preserved ejection fraction: the Ex-DHF-P trial. Eur. J. Prev. Cardiol. 22 (5), 582–593.
- Nunes, B.P., Flores, T.R., Mielke, G.I., Thume, E., Facchini, L.A., 2016. Multimorbidity and mortality in older adults: a systematic review and meta-analysis. Arch. Gerontol. Geriatr. 67, 130–138.
- Oerkild, B., Frederiksen, M., Hansen, J.F., Prescott, E., 2012. Home-based cardiac rehabilitation is an attractive alternative to no cardiac rehabilitation for elderly patients with coronary heart disease: results from a randomised clinical trial. BMJ Open 2 (6).
- Parker, S.G., Corner, L., Laing, K., Nestor, G., Craig, D., Collerton, J., et al., 2019. Priorities for research in multiple conditions in later life (multi-morbidity): findings from a James Lind Alliance Priority Setting Partnership. Age Ageing 48 (3), 401–406
- Pedersen, B.K., Saltin, B., 2015. Exercise as medicine evidence for prescribing exercise as therapy in 26 different chronic diseases. Scand. J. Med. Sci. Sport 25, 1–72.
- Pefoyo, A.J., Bronskill, S.E., Gruneir, A., Calzavara, A., Thavorn, K., Petrosyan, Y., et al., 2015. The increasing burden and complexity of multimorbidity. BMC Public Health 15, 415.
- Pibernik-Okanovic, M., Hermanns, N., Ajdukovic, D., Kos, J., Prasek, M., Sekerija, M., et al., 2015. Does treatment of subsyndromal depression improve depression-related and diabetes-related outcomes? A randomised controlled comparison of
- psychoeducation, physical exercise and enhanced treatment as usual. Trials 16, 305. Puhan, M.A., Gimeno-Santos, E., Cates, C.J., Troosters, T., 2016. Pulmonary rehabilitation following exacerbations of chronic obstructive pulmonary disease.
- Cochrane Database Syst. Rev. 12, CD005305. Reeuwijk, K.G., de Rooij, M., van Dijk, G.M., Veenhof, C., Steultjens, M.P., Dekker, J., 2010. Osteoarthritis of the hip or knee: which coexisting disorders are disabling? Clin. Rheumatol. 29 (7), 739–747.
- Rodriguez-Manas, L., Laosa, O., Vellas, B., Paolisso, G., Topinkova, E., Oliva-Moreno, J., et al., 2019. Effectiveness of a multimodal intervention in functionally impaired older people with type 2 diabetes mellitus. J. Cachexia Sarcopenia Muscle 10 (4), 721–733.
- Salisbury, C., Man, M.S., Bower, P., Guthrie, B., Chaplin, K., Gaunt, D.M., et al., 2018. Management of multimorbidity using a patient-centred care model: a pragmatic cluster-randomised trial of the 3D approach. Lancet 392 (10141), 41–50.
- Schneider, K.L., Panza, E., Handschin, B., Ma, Y., Busch, A.M., Waring, M.E., et al., 2016. Feasibility of pairing behavioral activation with exercise for women with type 2 diabetes and depression: the get it study pilot randomized controlled trial. Behav. Ther. 47 (2), 198–212.
- Schünemann, H.B.J., Guyatt, G., Oxman, A., 2013. GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013. The GRADE Working Group, p. 2013. Available from. guidelinedevelopment.org/ handbook.

#### A. Bricca et al.

- Sinnott, C., Mc Hugh, S., Browne, J., Bradley, C., 2013. GPs' perspectives on the management of patients with multimorbidity: systematic review and synthesis of qualitative research. BMJ Open 3 (9), e003610.
- Smith, S.M., Bayliss, E.A., Mercer, S.W., Gunn, J., Vestergaard, M., Wyke, S., et al., 2013. How to design and evaluate interventions to improve outcomes for patients with multimorbidity. J. Comorb. 3, 10–17.
- Smith, S.M., Wallace, E., O'Dowd, T., Fortin, M., 2016. Interventions for improving outcomes in patients with multimorbidity in primary care and community settings. Cochrane Database Syst. Rev. 3, CD006560.
- Smith, S.M., Wallace, E., Salisbury, C., Sasseville, M., Bayliss, E., Fortin, M., 2018. A core outcome set for multimorbidity research (COSmm). Ann. Fam. Med. 16 (2), 132–138.
- Soliman, G.S., Abdelbasset, W.K., 2019. Efficacy of aerobic training on pulmonary functions and depression in elderly COPD patients. J. Adv. Pharm. Educ. Res. 9 (4), 39–45.
- Stonerock, G.L., Hoffman, B.M., Smith, P.J., Blumenthal, J.A., 2015. Exercise as treatment for anxiety: systematic review and analysis. Ann. Behav. Med. 49 (4), 542–556.
- Vogeli, C., Shields, A.E., Lee, T.A., Gibson, T.B., Marder, W.D., Weiss, K.B., et al., 2007. Multiple chronic conditions: prevalence, health consequences, and implications for quality, care management, and costs. J. Gen. Intern. Med. 22, 391–395.
- Wesseling, J., Welsing, P.M.J., Bierma-Zeinstra, S.M.A., Dekker, J., Gorter, K.J., Kloppenburg, M., et al., 2013. Impact of self-reported comorbidity on physical and mental health status in early symptomatic osteoarthritis: the CHECK (Cohort Hip and Cohort Knee) study. Rheumatology 52 (1), 180–188.